Clinical Study of Valsartan and Salmeterol Fluticasone Aerosol in the Treatment of Patients with Bronchial Asthma and Hypertension
Objective To explore the clinical efficacy of valsartan and salmeterol fluticasone aerosol treatment in pa-tients with bronchial asthma(BA)and hypertension.Methods A total of 140 patients with BA and hypertension from May 2022 to July 2023 admitted to Qingzhou People's Hospital were selected as the study objects by target sampling method.According to different treatment methods,the patients were divided into a study group(n=70)and a control group(n=70).The control group was treated with benazepril combined with salmeterol and fluticasone powder inhala-tion,while the study group was treated with valsartan combined with salmeterol and fluticasone powder inhalation.The clinical efficacy,inflammatory cytokine levels,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was 94.29% (66/70),which was higher than the control group's 82.86% (58/70),and the difference was statistically significant(χ2=4.516,P<0.05).After treatment,the levels of interferon γ,interleukin 2,and interleukin 17 in both groups decreased,and the levels of interferon γ,interleukin 2,and interleukin 17 in the study group were lower than those in the control group,the differences were statistically significant(all P<0.05).There was no statistically significant difference in the total incidence of adverse reactions be-tween the two groups(P>0.05).Conclusion The combination of valsartan and salmeterol/fluticasone powder inhalation therapy has significant therapeutic effects on BA patients with hypertension,can inhibit inflammatory reactions,and has good safety.
NETL
NSTL
万方数据
